Moderna, Inc. · NASDAQ:MRNA
Moderna — Barclays Global Healthcare Conference 2025
4 slides from Moderna's conference presentation, Mar 11, 2025
Slide 1: Emerging Oncology Portfolio
Emerging Oncology Portfolio Presentation at Barclays Global Healthcare Conference March 11, 2025 © 2025 Moderna, Inc. All rights reserved.
Slide 2: Emerging oncology portfolio at Moderna uses mRNA technology to harness T-cells
Emerging oncology portfolio at Moderna uses mRNA technology to harness T-cells Cancer antigen T-cell engagers In vivo cell therapy therapies Multi-specific antibodies Tumor-targeting Off-the-shelf targeting different tumor CAR-M to modulate therapies targeting antigens and T cells tumor micro-enviro
Slide 3: Off-the-shelf cancer antigen therapies
Off-the-shelf cancer antigen therapies Therapies Development phase Immune-targeted Checkpoint Adaptive antigen therapy Immune Modulation Targets immunosuppressive Therapy (AIM-T) APC Suppressive immune cell cells and mechanisms (mRNA-4359) in Phase 2 Cancer antigen therapies Tumor-targeted Off-the-s
Slide 4: Confidential and Proprietary
Confidential and Proprietary